- Home
- KRUS vs ETNB Comparison
KRUS vs ETNB Comparison
Compare KRUS & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRUS
- ETNB
- Stock Information
- Founded
- KRUS 2008
- ETNB 2018
- Country
- KRUS United States
- ETNB United States
- Employees
- KRUS N/A
- ETNB N/A
- Industry
- KRUS Restaurants
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- KRUS Consumer Discretionary
- ETNB Health Care
- Exchange
- KRUS Nasdaq
- ETNB Nasdaq
- Market Cap
- KRUS 915.2M
- ETNB 867.4M
- IPO Year
- KRUS 2019
- ETNB 2019
- Fundamental
- Price
- KRUS $93.16
- ETNB $7.94
- Analyst Decision
- KRUS Buy
- ETNB Buy
- Analyst Count
- KRUS 8
- ETNB 7
- Target Price
- KRUS $84.88
- ETNB $30.33
- AVG Volume (30 Days)
- KRUS 110.7K
- ETNB 1.3M
- Earning Date
- KRUS 01-02-2025
- ETNB 11-07-2024
- Dividend Yield
- KRUS N/A
- ETNB N/A
- EPS Growth
- KRUS N/A
- ETNB N/A
- EPS
- KRUS N/A
- ETNB N/A
- Revenue
- KRUS $237,860,000.00
- ETNB N/A
- Revenue This Year
- KRUS $19.90
- ETNB N/A
- Revenue Next Year
- KRUS $20.65
- ETNB N/A
- P/E Ratio
- KRUS N/A
- ETNB N/A
- Revenue Growth
- KRUS 26.91
- ETNB N/A
- 52 Week Low
- KRUS $48.66
- ETNB $6.43
- 52 Week High
- KRUS $122.81
- ETNB $16.63
- Technical
- Relative Strength Index (RSI)
- KRUS 42.97
- ETNB 47.27
- Support Level
- KRUS $91.55
- ETNB $6.43
- Resistance Level
- KRUS $101.32
- ETNB $8.09
- Average True Range (ATR)
- KRUS 4.61
- ETNB 0.60
- MACD
- KRUS -1.58
- ETNB -0.07
- Stochastic Oscillator
- KRUS 7.38
- ETNB 48.24
About KRUS Kura Sushi USA Inc.
Kura Sushi USA Inc is a Japanese restaurant company. It operates revolving sushi chain restaurants in the United States. It provides access to the revolving and express conveyor belts, on-demand ordering screen, plate slot, and the Bikkura-Pon rewards machine. The company offers several dishes, including Dashi Olive Salmon, Tomago, Sweet Shrimp, Tuna, Garlic Tuna Steak, Salmon, among others. Geographically, it derives revenue from the United States of America.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).